Učitavanje...

Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

PURPOSE: To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 mutation carriers. METHODS: Analysis of pooled observational cohort data, self-reported at enrollment and at follow-up from the I...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Phillips, Kelly-Anne, Milne, Roger L., Rookus, Matti A., Daly, Mary B., Antoniou, Antonis C., Peock, Susan, Frost, Debra, Easton, Douglas F., Ellis, Steve, Friedlander, Michael L., Buys, Saundra S., Andrieu, Nadine, Noguès, Catherine, Stoppa-Lyonnet, Dominique, Bonadona, Valérie, Pujol, Pascal, McLachlan, Sue Anne, John, Esther M., Hooning, Maartje J., Seynaeve, Caroline, Tollenaar, Rob A.E.M., Goldgar, David E., Beth Terry, Mary, Caldes, Trinidad, Weideman, Prue C., Andrulis, Irene L., Singer, Christian F., Birch, Kate, Simard, Jacques, Southey, Melissa C., Olsson, Håkan L., Jakubowska, Anna, Olah, Edith, Gerdes, Anne-Marie, Foretova, Lenka, Hopper, John L.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2013
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3753701/
https://ncbi.nlm.nih.gov/pubmed/23918944
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.47.8313
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!